Cover Image
市場調查報告書

Sigmoid Pharma Limited:產品平台分析

Sigmoid Pharma Limited - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 277756
出版日期 內容資訊 英文 33 Pages
訂單完成後即時交付
價格
Back to Top
Sigmoid Pharma Limited:產品平台分析 Sigmoid Pharma Limited - Product Pipeline Review - 2016
出版日期: 2016年03月31日 內容資訊: 英文 33 Pages
簡介

Sigmoid Pharma Limited(原 Sigmoid Biotechnologies Ltd)是開發特殊醫藥品的製藥公司。該公司的治療藥的對象疾病為克隆氏症、移植物抗宿主病、移植排斥反應、乾癬、腹瀉、幽門螺桿菌胃幽門桿菌、大腸癌、腹瀉、麩質過敏症(乳糜瀉)、發炎性腸道疾病等。

本報告提供Sigmoid Pharma Limited的治療藥開發平台的現狀及各開發階段比較分析,各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估相關資訊等。

Sigmoid Pharma Limited的基本資料

  • Sigmoid Pharma Limited概要
  • 主要資訊
  • 企業資料

Sigmoid Pharma Limited:R&D概要

  • 主要的治療範圍

Sigmoid Pharma Limited:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式

Sigmoid Pharma Limited:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式 藥物研發中的產品/聯合治療模式

Sigmoid Pharma Limited:藥物簡介

Sigmoid Pharma Limited:開發平台分析

  • 按標的
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Sigmoid Pharma Limited:最近的開發平台趨勢

Sigmoid Pharma Limited:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08017CDB

Summary

Global Markets Direct's, 'Sigmoid Pharma Limited - Product Pipeline Review - 2016', provides an overview of the Sigmoid Pharma Limited's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Sigmoid Pharma Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Sigmoid Pharma Limited
  • The report provides overview of Sigmoid Pharma Limited including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Sigmoid Pharma Limited's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Sigmoid Pharma Limited's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Sigmoid Pharma Limited's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Sigmoid Pharma Limited
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sigmoid Pharma Limited's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Sigmoid Pharma Limited Snapshot
    • Sigmoid Pharma Limited Overview
    • Key Information
    • Key Facts
  • Sigmoid Pharma Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Sigmoid Pharma Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Sigmoid Pharma Limited - Pipeline Products Glance
    • Sigmoid Pharma Limited - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Sigmoid Pharma Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Sigmoid Pharma Limited - Drug Profiles
    • cyclosporine CR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cyclosporine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cyclosporine CR + cyclosporine IR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cyclosporine IR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • calcitonin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dimethyloxalylglycine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Helicobacter pylori [strain Hel-305] (multivalent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • celecoxib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Gastrointestinal and Immunological Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Agonize FXR for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Sigmoid Pharma Limited - Pipeline Analysis
    • Sigmoid Pharma Limited - Pipeline Products by Target
    • Sigmoid Pharma Limited - Pipeline Products by Route of Administration
    • Sigmoid Pharma Limited - Pipeline Products by Molecule Type
    • Sigmoid Pharma Limited - Pipeline Products by Mechanism of Action
  • Sigmoid Pharma Limited - Recent Pipeline Updates
  • Sigmoid Pharma Limited - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Sigmoid Pharma Limited, Key Information
  • Sigmoid Pharma Limited, Key Facts
  • Sigmoid Pharma Limited - Pipeline by Indication, 2016
  • Sigmoid Pharma Limited - Pipeline by Stage of Development, 2016
  • Sigmoid Pharma Limited - Monotherapy Products in Pipeline, 2016
  • Sigmoid Pharma Limited - Combination Treatment Modalities in Pipeline, 2016
  • Sigmoid Pharma Limited - Phase II, 2016
  • Sigmoid Pharma Limited - Phase I, 2016
  • Sigmoid Pharma Limited - Preclinical, 2016
  • Sigmoid Pharma Limited - Discovery, 2016
  • Sigmoid Pharma Limited - Pipeline by Target, 2016
  • Sigmoid Pharma Limited - Pipeline by Route of Administration, 2016
  • Sigmoid Pharma Limited - Pipeline by Molecule Type, 2016
  • Sigmoid Pharma Limited - Pipeline Products by Mechanism of Action, 2016
  • Sigmoid Pharma Limited - Recent Pipeline Updates, 2016

List of Figures

  • Sigmoid Pharma Limited - Pipeline by Top 10 Indication, 2016
  • Sigmoid Pharma Limited - Pipeline by Stage of Development, 2016
  • Sigmoid Pharma Limited - Monotherapy Products in Pipeline, 2016
  • Sigmoid Pharma Limited - Pipeline by Target, 2016
  • Sigmoid Pharma Limited - Pipeline by Route of Administration, 2016
  • Sigmoid Pharma Limited - Pipeline by Molecule Type, 2016
  • Sigmoid Pharma Limited - Pipeline Products by Mechanism of Action, 2016
Back to Top